News

"Dosing the first patient in our Phase 3 program is an important milestone for RDD Pharma in the development of our lead product candidate," said Jason Laufer, CEO

The announcement is part of a 2016 multimillion-dollar capital investment in instrumentation, which comes in the wake of ABC’s acquisition by California-based EAG in July of last year.

The approval pertains to patients who have locally advanced or metastatic urothelial carcinoma that progressed during or after platinum-based chemotherapy, or within 12 months of receiving either neoadjuvant

The variant, a twelve-letter deletion in the ASGR1 gene on chromosome 17, was discovered by analyzing the entire genome and clinical information from across the population of Iceland.

The proceeds from the financing will be used to advance Mitochon’s lead compound MP101, a first in class mitochondrial targeted neuro-protective agent, into human studies, as well as,

The application was submitted to the FDA by Novartis in March 2016 under the ofatumumab collaboration between Novartis and Genmab. Priority Review is an FDA designation for drugs

Uptravi is indicated for the long-term treatment of pulmonary arterial hypertension (PAH) in adult patients with WHO functional class (FC) II-III, either as combination therapy in patients insufficiently

The reduction in workforce, which affects employees from Catalyst’s commercial team, is part of Catalyst’s ongoing efforts to conserve cash as it works to complete the requirements for

The partnership intends to discover, develop and commercialize novel therapies based on Agios’ cellular metabolism research platform. Celgene will pay Agios $200m upfront for an initial four-year research